

#53907

Date: January 05, 2024

Subject: Titan Pharmaceuticals, Inc. - Reverse Split

Option Symbol: TTNP New Symbol: TTNP1 Date: 01/09/2024

Titan Pharmaceuticals, Inc. (TTNP) has announced a 1-for-20 reverse stock split. As a result of the reverse stock split, each TTNP Common Share will be converted into the right to receive 0.05 (New) Titan Pharmaceuticals, Inc. Common Shares. The reverse stock split will become effective before the market open on January 9, 2024.

## **Contract Adjustment**

Effective Date: January 9, 2024

Option Symbol: TTNP changes to TTNP1

Contract

Multiplier: 1

Strike Divisor: 1

**New Multiplier:** 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

New Deliverable

**Per Contract:** 5 (New) Titan Pharmaceuticals, Inc. (TTNP) Common Shares

**CUSIP:** TTNP (New): 888314705

## **Pricing**

The underlying price for TTNP1 will be determined as follows:

TTNP1 = 0.05 (TTNP)

## Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to

investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.